Search
Aldeyra Therapeutics Inc
ALDXAdd to Watchlist
2.270USD
-0.160-6.58%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
136.93MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-6.58%
5 Days
+26.11%
1 Month
+38.41%
6 Months
-51.39%
Year to Date
-56.18%
1 Year
-43.25%
Key Figures
2.410Open
2.530High
2.12MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.51%Turnover Ratio
2.430Prev. Close
2.250Low
3.48MTurnover
LossP/E Static
3.25P/B
0.00%Div Yield TTM
-34.28%ROA
6.17552wk High
1.26Volume Ratio
-55.85MNet Profit
60.32MShares
-0.4550EPS TTM
1.18Beta
-51.76%ROE
1.07052wk Low
11.51%Amplitude
--Gross Margin
136.93MMarket Cap
5.57Reward/Risk
5.50%Risk Rate
TradingKey Stock Score of Aldeyra Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Aldeyra Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 103 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.20.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aldeyra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Aldeyra Therapeutics Inc Highlights
StrengthsRisks
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Overvalued
The company’s latest PE is -4.99, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.55M shares, decreasing 6.95% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 38.09K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.45.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
7.200
Target Price
+251.22%
Upside Space
Aldeyra Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aldeyra Therapeutics Inc Info
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Ticker SymbolALDX
CompanyAldeyra Therapeutics Inc
CEOBrady (Todd C)
Websitehttps://www.aldeyra.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52822.700
-19.800 (-0.04%)
29615.600
+304.200 (+1.04%)
7498.300
+26.800 (+0.36%)
14953.000
+150.000 (+1.01%)
69501.000
+1353.000 (+1.99%)
6371.200
+18.400 (+0.29%)
68.543
+0.199 (+0.29%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4180.600
+58.690 (+1.42%)
FAQs
What is the current price of Aldeyra Therapeutics Inc (ALDX)?
The current price of Aldeyra Therapeutics Inc (ALDX) is 2.27.
What is the symbol of Aldeyra Therapeutics Inc?
The ticker symbol of Aldeyra Therapeutics Inc is ALDX.
What is the 52-week high of Aldeyra Therapeutics Inc?
The 52-week high of Aldeyra Therapeutics Inc is 6.17.
What is the 52-week low of Aldeyra Therapeutics Inc?
The 52-week low of Aldeyra Therapeutics Inc is 1.07.
What is the market capitalization of Aldeyra Therapeutics Inc?
The market capitalization of Aldeyra Therapeutics Inc is 136.93M.
Is Aldeyra Therapeutics Inc (ALDX) currently rated as Buy, Hold, or Sell?
According to analysts, Aldeyra Therapeutics Inc (ALDX) has an overall rating of Buy, with a price target of 7.20.
What is the Earnings Per Share (EPS TTM) of Aldeyra Therapeutics Inc (ALDX)?
The Earnings Per Share (EPS TTM) of Aldeyra Therapeutics Inc (ALDX) is -0.56.